Study links COPD drugs to higher cardiovascular risks

05/30/2013 | AAFP News Now

Cardiovascular risks are higher for older patients who begin long-acting beta agonists and long-acting anticholinergics to treat chronic obstructive pulmonary disease, Canadian researchers reported in JAMA Internal Medicine. Prescott Woodruff, M.D., of the University of California, San Francisco, wrote in a commentary that while the drugs are mainstays of COPD treatment, the safety issues brought up by the study put the medications in a gray area.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC